Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02508649 · ClinicalTrials.gov registry record · Phase 2
Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial
A Phase 2 study, sponsored by Ferring Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 868
- Enrollment target
NCT02508649: Clinical Trial Phase 2 study, sponsored by Ferring Pharmaceuticals.
NCT02508649 is a Phase 2 study that was terminated before completion, run by Ferring Pharmaceuticals. The registered enrollment target is 868 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (553% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02508649, a Phase 2 study, was terminated before completion, sponsored by Ferring Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 868 participants
- Enrollment target
Study Summary
This is a double-blind, randomised, placebo-controlled, two-part adaptive clinical trial. The trial is designed to investigate the efficacy and safety of multiple dosing regimens of selepressin and to confirm the efficacy and safety of one dosing regimen in treatment of adult patients with septic shock requiring vasopressor.
Primary Outcome
Composite endpoint defined as number of days from start of treatment to 30 days thereafter during which subject is: 1. Alive. However, if patient dies within these 30-days then PVFDs will be zero even if there is a period during which subject is alive and free of both vasopressor treatment and mechanical ventilation; 2. Free of treatment with vasopressors: Less than 60 min during any contiguous 24-h period. If a patient requires vasopressors longer than 60 min in total during any 24-h period, t
Interventions
- DRUG placebo
- DRUG selepressin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 868 participants |
| Start Date | 2015-07 |
| Est. Completion | 2018-02-26 |
| Phase | Phase 2 |
Why NCT02508649 stopped before completion
NCT02508649 is an interventional study that assigns participants to a tested intervention. The registered 868 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (553% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02508649 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02508649 about?
NCT02508649 is a clinical study titled "Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial". This is a double-blind, randomised, placebo-controlled, two-part adaptive clinical trial. The trial is designed to investigate the efficacy and safety of multiple dosing regimens of selepressin and to confirm the efficacy and safety of one dosing regimen in treatment of adult patients with septic sh...
What is the current status of trial NCT02508649?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 868 participants. The study started on 2015-07. Estimated completion is 2018-02-26.
What interventions are being tested in trial NCT02508649?
The interventions under investigation include: placebo (DRUG), selepressin (DRUG).
Who is sponsoring clinical trial NCT02508649?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02508649's enrollment target sits among peer trials
868 33rd of 2000 higher than 1,968 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06077760 · 868 participants · Phase 3
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
- NCT06822790 · 869 participants · Phase 3
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
- NCT04933552 · 867 participants
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
- NCT04097145 · 870 participants · NA
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia